Show simple item record

dc.contributor.authorChildress, A.
dc.contributor.authorMehrotra, S.
dc.contributor.authorGobburu, J.
dc.date.accessioned2019-05-17T13:21:15Z
dc.date.available2019-05-17T13:21:15Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85041025944&doi=10.1089%2fcap.2017.0044&partnerID=40&md5=3b49d38d0125ec7b63e4d724ec0fad87
dc.identifier.urihttp://hdl.handle.net/10713/9175
dc.description.abstractObjective: Current extended-release (ER) formulations of psychostimulants used for treatment of attention-deficit/hyperactivity disorder (ADHD) provide an extended duration of ADHD symptom control; however, the onset of efficacy can be protracted and variable, leaving the early morning untreated. The primary objective was to characterize the single-dose pharmacokinetics and tolerability of HLD200, an evening-dosed, delayed-release (DR) and ER formulation of methylphenidate (MPH), in healthy adults and in adolescents and children with ADHD. Methods: The pharmacokinetics and tolerability of a single, oral evening dose of HLD200 (54 mg) were evaluated in two single-center open-label studies: the first in healthy adults (n = 12) and the second in adolescents (n = 18) and children (n = 11) with ADHD. Primary pharmacokinetic endpoints were the rate and extent of MPH absorption (Cmax and area under the curve [AUC]) and time to peak concentration (Tmax). These parameters were calculated using noncompartmental analysis. Results: HLD200 produced a pharmacokinetic profile characterized by an 8- to 10-hour delay in MPH release, followed by a period of extended controlled release, resulting in an ascending absorption profile that coincided with the early morning and afternoon. Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively. Intersubject variability in the mean time to achieve ascending plasma MPH concentrations of 2, 3, 4, and 5 ng/mL was low (CV: 7.8%-17.7%). Conclusions: Evening-dosed HLD200 produces the intended DR and ER pharmacokinetic profile that provides a consistent predictable delay in initial MPH release until the early morning, followed by extended release across the day. The body weight-adjusted pharmacokinetics of HLD200 were similar between adults and adolescents and children with ADHD. Copyright Ann Childress et al. 2017; Published by Mary Ann Liebert, Inc.en_US
dc.description.sponsorshipThese studies were presented as an abstract at the American Professional Society of ADHD and Related Disorders Annual Meeting, Washington, DC, January 13-15, 2017. Funding: Ironshore Pharmaceuticals and Development, Inc. funded this study.en_US
dc.description.urihttps://dx.doi.org/10.1089/cap.2017.0044en_US
dc.language.isoen_USen_US
dc.publisherMary Ann Liebert Inc.en_US
dc.relation.ispartofJournal of Child and Adolescent Psychopharmacology
dc.subjectattention-deficit/hyperactivity disorderen_US
dc.subjectdelayed-releaseen_US
dc.subjectextended-releaseen_US
dc.subjectmethylphenidateen_US
dc.subjectpharmacokineticsen_US
dc.titleSingle-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorderen_US
dc.typeArticleen_US
dc.identifier.doi10.1089/cap.2017.0044


This item appears in the following Collection(s)

Show simple item record